Target Name: CDCP2
NCBI ID: G200008
Other Name(s): CDCP2_HUMAN | CUB domain containing protein 2, transcript variant 2 | CUB domain-containing protein 2 | CUB domain-containing protein 2 (isoform 2) | CDCP2 variant 2 | CUB domain containing protein 2

CDCP2: A Potential Drug Target and Biomarker for the Treatment of Human Disease

Abstract:

CDCP2, a gene encoding a protein known as CDCP2, has been identified as a potential drug target and biomarker for the treatment of various human diseases. CDCP2 has been shown to play a crucial role in the development and progression of a range of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will review the current research on CDCP2 as a drug target and biomarker, and discuss the potential clinical applications of targeting this protein in human disease.

Introduction:

CDCP2 is a gene that encodes a protein with unique structural features that give it a unique position in the cell. CDCP2 has been shown to play a crucial role in the development and progression of various human diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its functions and interactions with other proteins have been extensively studied, and its potential as a drug target and biomarker have been proposed.

CDCP2 and Cancer:

Cancer is a leading cause of human death, with over 20% of all deaths due to cancer. The development and progression of cancer is a complex process that involves the interplay of multiple genetic and epigenetic factors. CDCP2 has been shown to contribute to the development and progression of various cancers, including breast, ovarian, and colorectal cancers.

CDCP2 has been shown to promote the growth and survival of cancer cells. It has been shown to enhance the formation of cancer-initiating cells, and to contribute to the development of cancer-associated hallmark processes, such as the formation of blood vessels, invasiveness, and metastasis.

CDCP2 and Neurodegenerative Disorders:

Neurodegenerative disorders are a group of progressive diseases that affect the nervous system, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells, and can result in a range of symptoms, including cognitive decline, motor impairment, and behavioral changes.

CDCP2 has been shown to contribute to the development and progression of neurodegenerative disorders. It has been shown to promote the migration of neural stem cells to the developing brain, and to contribute to the formation of neurofibrillary tangles and senile plaques, which are hallmark features of neurodegenerative disorders.

CDCP2 and Autoimmune Diseases:

Autoimmune diseases are a group of diseases in which the immune system attacks the body's own tissues, leading to inflammation and damage. These diseases include rheumatoid arthritis, lupus, and multiple sclerosis.

CDCP2 has been shown to contribute to the development and progression of autoimmune diseases. It has been shown to promote the production of immune cells that contribute to the development of autoimmune diseases, and to enhance the formation of immune-invading molecules in the body.

CDCP2 as a Drug Target:

CDCP2 has the potential to serve as a drug target for the treatment of various human diseases. Its functions and interactions with other proteins have been extensively studied, and its potential drug targets have been identified.

One potential drug target for CDCP2 is the inhibition of its activity. This can be achieved through a variety of methods, including the use of small molecules, antibodies, or other therapeutic agents that target CDCP2 directly or its interacting proteins.

Another potential drug target for CDCP2 is the modulation of its expression. This can be achieved through the use of drugs that regulate the activity of genes involved in CDCP2 expression, such as RNA interference or DNA methylation.

CDCP2 as a Biomarker:

CDCP2 has the potential to serve as a biomarker for the diagnosis and monitoring of various human diseases. Its expression and activity have been shown to be altered in a range of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The expression of CDCP2 has been shown to be increased in a range of human diseases, including cancer, neurodegenerative disorders,

Protein Name: CUB Domain Containing Protein 2

More Common Targets

CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3